307 related articles for article (PubMed ID: 26452232)
1. The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients.
Kwon O; Jang HM; Jung HY; Kim YS; Kang SW; Yang CW; Kim NH; Choi JY; Cho JH; Kim CD; Kim YL; Park SH;
PLoS One; 2015; 10(10):e0140241. PubMed ID: 26452232
[TBL] [Abstract][Full Text] [Related]
2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
3. Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
Bae MN; Kim SH; Kim YO; Jin DC; Song HC; Choi EJ; Kim YL; Kim YS; Kang SW; Kim NH; Yang CW; Kim YK
PLoS One; 2015; 10(11):e0143348. PubMed ID: 26588085
[TBL] [Abstract][Full Text] [Related]
4. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.
Ogawa T; Shimizu H; Kyono A; Sato M; Yamashita T; Otsuka K; Nitta K
Int Urol Nephrol; 2014 Jan; 46(1):151-9. PubMed ID: 23807369
[TBL] [Abstract][Full Text] [Related]
5. Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients.
Minutolo R; Conte G; Cianciaruso B; Bellizzi V; Camocardi A; De Paola L; De Nicola L
Nephrol Dial Transplant; 2012 Jul; 27(7):2880-6. PubMed ID: 22319218
[TBL] [Abstract][Full Text] [Related]
6. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan.
Fukuma S; Yamaguchi T; Hashimoto S; Nakai S; Iseki K; Tsubakihara Y; Fukuhara S
Am J Kidney Dis; 2012 Jan; 59(1):108-16. PubMed ID: 21890255
[TBL] [Abstract][Full Text] [Related]
7. Individualized anemia management in a dialysis facility - long-term utility as a single-center quality improvement experience
.
Gaweda AE; Jacobs AA; Aronoff GR; Brier ME
Clin Nephrol; 2018 Oct; 90(4):276-285. PubMed ID: 30049300
[TBL] [Abstract][Full Text] [Related]
8. Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study.
Fort J; Cuevas X; García F; Pérez-García R; Lladós F; Lozano J; Martín-Malo A;
Nephrol Dial Transplant; 2010 Aug; 25(8):2702-10. PubMed ID: 20176608
[TBL] [Abstract][Full Text] [Related]
9. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
Regidor DL; Kopple JD; Kovesdy CP; Kilpatrick RD; McAllister CJ; Aronovitz J; Greenland S; Kalantar-Zadeh K
J Am Soc Nephrol; 2006 Apr; 17(4):1181-91. PubMed ID: 16565261
[TBL] [Abstract][Full Text] [Related]
10. Low hemoglobin levels and hypo-responsiveness to erythropoiesis-stimulating agent associated with poor survival in incident Japanese hemodialysis patients.
Akizawa T; Saito A; Gejyo F; Suzuki M; Nishizawa Y; Tomino Y; Tsubakihara Y; Akiba T; Hirakata H; Watanabe Y; Kawanishi H; Bessho M; Udagawa Y; Aoki K; Uemura Y; Ohashi Y;
Ther Apher Dial; 2014 Oct; 18(5):404-13. PubMed ID: 24571446
[TBL] [Abstract][Full Text] [Related]
11. Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time.
Robinson BM; Joffe MM; Berns JS; Pisoni RL; Port FK; Feldman HI
Kidney Int; 2005 Nov; 68(5):2323-30. PubMed ID: 16221236
[TBL] [Abstract][Full Text] [Related]
12. Association of mortality and hospitalization with achievement of adult hemoglobin targets in adolescents maintained on hemodialysis.
Amaral S; Hwang W; Fivush B; Neu A; Frankenfield D; Furth S
J Am Soc Nephrol; 2006 Oct; 17(10):2878-85. PubMed ID: 16943308
[TBL] [Abstract][Full Text] [Related]
13. Mortality and cardiovascular morbidity associated with haemoglobin levels: a pooled analysis of randomised controlled trials.
Locatelli F; de Francisco A; Deray G; Fliser D; Armstrong G; Dougherty FC; Ehrhard P
Nephron Clin Pract; 2014; 128(3-4):323-32. PubMed ID: 25503585
[TBL] [Abstract][Full Text] [Related]
14. Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients.
Bradbury BD; Critchlow CW; Weir MR; Stewart R; Krishnan M; Hakim RH
Nephrol Dial Transplant; 2009 Mar; 24(3):919-25. PubMed ID: 18840893
[TBL] [Abstract][Full Text] [Related]
15. Chapter 8 Haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2010: national and centre-specific analyses.
Webb L; Gilg J; Wilkie M
Nephron Clin Pract; 2012; 120 Suppl 1():c145-74. PubMed ID: 22964566
[TBL] [Abstract][Full Text] [Related]
16. Association of dialysis facility-level hemoglobin measurement and erythropoiesis-stimulating agent dose adjustment frequencies with dialysis facility-level hemoglobin variation: a retrospective analysis.
Khan I; Krishnan M; Kothawala A; Ashfaq A
BMC Nephrol; 2011 May; 12():22. PubMed ID: 21595975
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and predictors of the sub-target Hb level in children on dialysis.
van Stralen KJ; Krischock L; Schaefer F; Verrina E; Groothoff JW; Evans J; Heaf J; Ivanov D; Kostic M; Maringhini S; Podracká L; Printza N; Pundziene B; Reusz GS; Vondrak K; Jager KJ; Tizard EJ;
Nephrol Dial Transplant; 2012 Oct; 27(10):3950-7. PubMed ID: 22740719
[TBL] [Abstract][Full Text] [Related]
18. Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients.
Weinhandl ED; Gilbertson DT; Collins AJ
Am J Nephrol; 2011; 34(4):298-308. PubMed ID: 21829009
[TBL] [Abstract][Full Text] [Related]
19. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.
Kalantar-Zadeh K; Lee GH; Miller JE; Streja E; Jing J; Robertson JA; Kovesdy CP
Am J Kidney Dis; 2009 May; 53(5):823-34. PubMed ID: 19339087
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of Hemoglobin Cycling and Its Clinical Impact on Outcomes in Thai End-Stage Renal Disease Patients Treated with Hemodialysis and Erythropoiesis-Stimulating Agent.
Thanakitcharu P; Jirajan B
J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S28-37. PubMed ID: 27266213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
